Neptune Technologies & Bioressources Inc. Reports Second Quarter Results - Record EBITDA
Friday, January 26 2007

Neptune Technologies & Bioressources Inc. Reports Second Quarter Results - Record EBITDA

Laval, Quebec, Canada, January 26th, 2007 - Neptune Technologies & Bioressources Inc., (TSX Venture Exchange: NTB), «Neptune» today announced its results for the Second quarter ended November 30th, 2006. Neptune recorded its highest EBITDA quarter to date.

Neptune’s Highlights:

  • Second Quarter ended November 30th, 2006
    • Operating revenues increased by 44% to $1,947,000 compared to $1,354,000, for the second quarter of 2005.
    • EBITDA increased by 123% to $546,000 compared to $245,000 during the second quarter of 2005.
    • EBITDA margin increased by 55% from 18% to 28% respectively for the quarters ending November 30, 2005 and 2006.
    • Net loss from continuing operations decreased to $449,000, or $0.013 per share compared to $453,000, or $0.018 per share, for the second quarter in 2005.
  • Six months ended November 30th, 2006
    • Operating revenues increased by 15% to $3,499,000 compared to $3,038,000 for the same period of 2005.
    • EBITDA increased by 45% to $849,000 compared to $587,000 for the same period of 2005.
    • EBITDA margin increased by 26% from 18% to 24% respectively for the six months periods ending November 30, 2005 and 2006.
    • Net loss from continuing operations decreased by 13%, to $734,000, or $0.021 per share, compared to $842,000, or $0.033 per share, for the same period of 2005.

“The reorganisation of our Sales and Marketing department is starting to pay off. Neptune has realized its best EBITDA quarter and second best sales quarter to date. We are very pleased with Neptune’s overall performance even though the existing stock option plan in conjunction with the significant share price increase over the six months period ending November 30, 2006 affected the bottom line without fortunately any impact on the cash flow,” stated André Godin, Vice-President, Administration and Finance for Neptune Technologies & Bioressources Inc.

About Neptune Technologies & Bioressources Inc. : https://www.neptunebiotech.com
Neptune Technologies & Bioressources Inc. develops high value added nutritional products from underexploited marine biomasses, such as krill, with its patented extraction process (Neptune OceanExtract™). Using an exclusive process, Neptune Technologies & Bioressources Inc. is well positioned in the $182 billion global nutrition market (Nutrition Business Journal, Oct/Nov 2004) of health and wellness concepts.

Natural biomass extraction is now playing an important role in developing nutrigenomics, the next wave in nutritional research. Through strategic alliances and partnerships, as well as through clinical studies, the Company continues to demonstrate the immense beneficial effects of these products. The Company develops and markets new formulas and new products for specific applications in high growth markets such as the nutraceutical, cosmeceutical, biopharmaceutical and nutrigenomics markets.

Neither NASDAQ nor TSX venture exchange accepts responsibility for the adequacy or accuracy of this press release.
Neptune Technologies and Acasti Pharma Contact:
Neptune Technologies & Bioressources Inc.
Acasti Pharma Inc.
Toni Rinow, Ph.D., MBA
Corporate Development & Investor Relations
(450) 687-2262
This e-mail address is being protected from spambots, you need JavaScript enabled to view it
# # #
Statements in this press release that are not statements of historical or current fact constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. Such forward-looking statements involve known and unknown risks, uncertainties, and other unknown factors that could cause the actual results of the Company to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms "believes," "belief," "expects," "intends," "anticipates," "will," or "plans" to be uncertain and forward-looking. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company's reports filed with the Securities and Exchange Commission and the Canadian securities commissions.
 

We communicate

NTB (TSX) CAN$ 1.93 +0.03
NEPT (NASDAQ) US$ 1.898 +0.068
 

press releases

Investor Relations Contact NEPTUNE TECHNOLOGIES & BIORESSOURCES